Elevated Glucose Attenuates Human Insulin Gene Promoter Activity in INS-1 Pancreatic ß-Cells via Reduced Nuclear Factor Binding to the A5/Core and Z Element

Maria F. Pino1, Diana Z. Ye1, Katrina D. Linning, Christopher D. Green, Barton Wicksteed, Vincent Poitout and L. Karl Olson

Departments of Physiology (M.F.P., K.D.L., L.K.O.), Pharmacology (D.Z.Y.), and Biochemistry and Molecular Biology (C.D.G.), Michigan State University, East Lansing, Michigan 48824; Pacific Northwest Research Institute (B.W., V.P.), Seattle, Washington 98122; and Department of Medicine (V.P.), University of Washington, Seattle, Washington 98195

Address all correspondence and requests for reprints to: L. Karl Olson, Ph.D., Michigan State University, Department of Physiology, 3176 Biomedical and Physical Sciences Building, East Lansing, Michigan 48824. E-mail: olsonla{at}msu.edu.


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 
Chronic exposure of pancreatic ß-cells to elevated glucose reduces insulin gene promoter activity, and this is associated with diminished binding of two ß-cell-enriched transcription factors, Pdx-1 and MafA. In this study using INS-1 ß-cells, overexpression of MafA, but not Pdx-1, was able to restore expression of a human insulin reporter gene (–327 to +30 bp) suppressed by elevated glucose. At issue, however, was that MafA also markedly stimulated an insulin reporter gene (–230 to +30 bp) that was only marginally suppressed by glucose, suggesting that glucose-mediated suppression of the insulin promoter involved elements upstream of –230. Using serial truncations and minienhancer constructs of the human insulin promoter, the majority of glucose suppression was localized to regulatory elements between –327 and –261. Nuclear extracts from INS-1 cells exposed to elevated glucose had reduced binding activities to the A5/core (–319 to –307), and to a palindrome (–284 to –267) and an E box (–273 to –257, E3) contained within the Z element. The A5/core binding complex was determined to contain MafA, Pdx-1, and an A2-like binding factor. Two minienhancer constructs containing the A5/core were suppressed by glucose and strongly activated by MafA. Glucose-mediated suppression of the Z minienhancer was not attenuated by overexpression of MafA or Pdx-1. Site-directed mutation of the A5/core, palindrome, and E3 elements attenuated glucose-mediated suppression. These data indicate that glucose suppression of human insulin promoter activity in INS-1 cells involves reduced binding of MafA to the A5/core. Changes in nuclear factor binding to the Z element, which functions as a strong activator element in primary islets and a negative regulatory element in simian virus 40 or T antigen transformed ß-cell lines, also participate in glucose suppression of insulin promoter activity.


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 
GLUCOSE EXERTS A number of positive effects on pancreatic ß-cells, including stimulation of insulin secretion, insulin gene transcription and translation, and cell growth, that contribute to the tight control of glucose homeostasis. Chronic hyperglycemia, however, can negatively impact ß-cell function, in part, by altering ß-cell gene expression (1, 2) and survival (3) through a process called glucose toxicity. One of the hallmarks of glucose toxicity is a reduction in insulin gene expression (1, 2, 4, 5, 6, 7, 8, 9, 10, 11, 12) that results from decreased insulin promoter activity (4, 5, 6, 13, 14). In vitro and in vivo studies have shown that prolonged elevations of glucose reduce the expression and/or binding of ß-cell-enriched transcription factors including the pancreatic duodenal homeobox factor 1 (Pdx-1) (1, 6, 7, 8, 9, 10, 11, 12, 14, 15) and the C1 activator [also known as RIPE3b1/MafA (16, 17)] (5, 6, 13, 18), and increased expression of CAAT/enhancer binding protein ß (C/EBPß) (8, 19) and c-Myc (11, 20). Because Pdx-1 plays a critical role in pancreas development (21, 22, 23) and maintenance of ß-cell function by regulating the expression of ß-cell-enriched genes, including insulin, glucose transporter 2, and glucokinase (24, 25, 26, 27), a loss of Pdx-1 expression and/or binding is predicted to markedly affect pancreatic ß-cell phenotype and function.

We have previously reported that exposure of the highly differentiated rat insulinoma cell line, INS-1, to elevated glucose concentrations suppressed insulin promoter activity and mRNA levels within 24 h (6). The suppression of insulin promoter activity was associated with a reduction in the binding activities of both Pdx-1 and C1 activator. It is shown herein that overexpression of Pdx-1 in INS-1 cells was insufficient to prevent glucose suppression of insulin promoter activity. In contrast, MafA overexpression strongly stimulated insulin promoter in cells cultured in both low and high glucose. At issue, however, is that MafA can activate a human insulin reporter gene regulated by sequences from –230 to +30 that is only marginally suppressed by elevated glucose. This observation prompted us to assess whether other sequences proximal to the –230 insulin promoter were involved in glucose suppression of insulin gene transcription. Serial truncation analysis of a human insulin reporter gene demonstrated that the majority of glucose-mediated suppression of insulin promoter activity maps to regulatory elements between –327 and –261, significantly upstream from the well-characterized A3 and A1 elements, and C1 element that serve as binding sites for Pdx-1 and MafA, respectively. Previous studies have shown that this region of the human insulin promoter contains the Z element (–292 to –243) that functions both as a strong glucose-responsive transcriptional enhancer in primary islet cells (28, 29) and as a negative regulatory element (NRE) in simian virus 40 (SV40) or T antigen immortalized ß-cell lines and non-ß-cells (29, 30, 31). This region also contains the A5 element, which resembles a consensus Pdx-1 binding site, and the highly conserved enhancer core sequence (32), which binds a nuclear factor complex enriched in ß-cells (33). Because of the complexity of interactions in this region of the human insulin promoter, we have employed a number of human insulin minienhancers (five copies of a regulatory region in tandem) and a series of mutations in the human insulin promoter to map elements involved in glucose suppression of the insulin promoter. Finally, we have investigated glucose-mediated changes in binding activities to these upstream regulatory elements.


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 
Glucose Regulates Insulin Promoter Activity in a Biphasic Manner in INS-1 Cells and Isolated Rat Islets
Previous studies have shown that exposure of INS-1 cells to 16.7 mM glucose for 24–48 h leads to marked suppression of insulin promoter activity (6). To assess the glucose dependency of this effect, INS-1 cells were transiently transfected with an insulin chloramphenicol acetyltransferase (CAT) reporter gene [INS(–327)CAT] in which CAT gene expression is regulated by –327 to +30 of the human insulin promoter (4). Several key regulatory elements have been identified in this promoter region including the A1 (–82 to –77 bp) and A3 (–215 to –210 bp), C1 (–124 to –116 bp), and E1 (–237 to –229 bp) (reviewed in Ref.34), which serve as binding sites for ß-cell-enriched transcription factors including Pdx-1 (35), MafA (16, 17), and BETA2 (36), respectively (Fig. 1AGo). Additional upstream regulatory elements have been identified including the A5 (–319 to –313 bp), enhancer core (–313 to –307 bp), Z (–292 to –261 bp), and NRE (–279 to –265 bp) that can bind unidentified ß-cell-enriched nuclear factors (29, 31, 33). Incubation of the cells in 6 mM glucose for 48 h increased –327 insulin promoter activity 3.6 ± 0.6-fold (P < 0.01) compared with cells incubated in 2 mM glucose (Fig. 1BGo). In contrast, incubation of cells in glucose concentrations greater than 8 mM glucose led to a concentration-dependent reduction in insulin promoter activity. Overall, incubation of INS-1 cells in media containing 16.7 mM glucose led to an 82.9 ± 1.4% (P < 0.005) reduction in insulin promoter activity compared with cells incubated in 4 mM glucose. Reductions in insulin promoter activity were not due to osmotic stress because treatment of INS-1 cells with 4 mM glucose plus 12.7 mM mannitol caused no significant change in insulin promoter activity (data not shown).



View larger version (20K):
[in this window]
[in a new window]
 
Fig. 1. Glucose Regulates Insulin Promoter Activity in a Biphasic Manner in INS-1 Cells and Isolated Rat Islets

A, Schematic representation of human insulin promoter sequences from –327 to –75 showing the location of known regulatory elements and some of the identified transcription factors. Binding complexes that contain uncharacterized transcription factors are italicized. Question marks represent unidentified ß-cell-enriched binding factors. The Z element and NRE contain a palindrome sequence and E box that are labeled Pal and E3, respectively. B, INS-1 cells were transiently transfected with 1 µg INS(–327)CAT and incubated in media containing the indicated glucose concentrations. Cells were harvested 48 h after transfection, and CAT activity was assayed. CAT activities are reported as the mean ± SEM for four independent experiments. C, Glucose repression of the –327 insulin promoter [INS(–327)CAT] vs. the –230 insulin promoter [INS(–230)CAT]. CAT activities are reported as the mean ± SEM for five independent experiments. *, P < 0.05 for CAT expression in cells treated with 4 mM vs. 16.7 mM glucose. D, Rat islets were infected with Ad-RIP1-Luc or Ad-CMV-Luc and incubated in media containing the indicated glucose concentrations. Cells were harvested 24 h after glucose treatment, and luciferase activity was assayed. Results are expressed as the ratio of Ad-RIP1-Luc to Ad-CMV-Luc activity. NFAT, Nuclear factor of activated T cells; USF, upstream stimulatory factor; CRE, cAMP response element; CREB, CRE-binding protein; CREM, CRE modulator; NFY, nuclear factor Y; HEB, HeLa E-box-binding factor.

 
We have previously reported that incubation of INS-1 cells in 16.7 mM glucose for 48 h also caused a reduction in binding activities of Pdx-1 and the C1 activator [RIPE 3b1/MafA (16, 17)] (6). Because the A1 and A3 elements and the C1 element serve as binding sites for Pdx-1 and MafA, respectively, a more simplified reporter gene regulated by promoter sequences from –230 to +30 [INS(–230)CAT] was examined for glucose-mediated suppression. Deletion of insulin promoter sequences from –327 to –231 led to a large (68%) reduction in expression of INS(–230)CAT when compared with INS(–327)CAT (Fig. 1CGo). More importantly, deletion of the upstream promoter sequences led to an unexpected reduction in glucose-mediated suppression of insulin promoter activity. It should also be noted that activities of the –230 and –327 promoters were nearly equivalent when cells were incubated in high glucose. Thus, major sites of glucose-mediated suppression must reside in insulin promoter sequences upstream of –230.

To assess glucose regulation of insulin promoter activity in primary rat islets, islets were infected with an adenovirus that has the luciferase gene under transcription control of the rat 1 insulin gene promoter sequences –310 to –12 (Ad-RIP1-Luc), or with a control adenovirus encoding for luciferase under the control of the cytomegalovirus (CMV) promoter (Ad-CMV-Luc). Infected islets were cultured for 24 h with increasing glucose concentrations, and luciferase activity was measured. As observed with INS-1 cells, glucose regulated the rat 1 insulin promoter in a biphasic manner (Fig. 1DGo), with an initial increase up to 16.7 mM and a marked decrease at 22.2 mM glucose.

MafA, but not Pdx-1, Increases Insulin Promoter Activity in INS-1 Cells Cultured in Elevated Glucose Concentrations
Pdx-1 or MafA were overexpressed in INS-1 cells to test their relative abilities to attenuate glucose-mediated suppression of insulin promoter activity. Increased expression of Pdx-1 in cells treated with elevated glucose was unable to restore activity of the –327 insulin promoter [INS(–327)CAT] (Fig. 2AGo). In contrast, increased expression of MafA strongly activated the –327 insulin promoter under identical culture conditions (Fig. 2BGo). MafA also strongly activated the –230 insulin promoter [INS(–230)CAT] (Fig. 2CGo), whereas Pdx-1 remained completely ineffective (data not shown). These results can be interpreted in two ways: either that loss of MafA, but not Pdx-1, accounts for loss of insulin promoter activity, or that MafA increases insulin promoter activity as a whole and thus overrides the inhibition by glucose without representing a mechanism of action of glucose per se. This latter possibility is supported by the observation that the –230 insulin promoter was not suppressed by elevated glucose to the level seen for the –327 insulin promoter (Fig. 1CGo).



View larger version (14K):
[in this window]
[in a new window]
 
Fig. 2. MafA, but Not Pdx-1, Increases Insulin Promoter Activity in INS-1 Cells Cultured in Elevated Glucose Concentrations

INS-1 cells were transiently transfected with 1 µg INS(–327)CAT or INS(–230)CAT and the indicated amounts of pCR3.1-CMV-Pdx-1 or pCR3.1-CMV-MafA expression plasmids. Equivalent amounts of expression plasmid (0.5 µg) was transfected per well by the addition of pCR3.1-CMV containing no insert. Cells were then incubated for 48 h in 4 or 16.7 mM glucose, after which CAT activity was assayed. A, Effect of Pdx-1 overexpression on INS(–327)CAT expression. Data are mean ± SEM for four independent experiments. B, Effect of MafA overexpression on INS(–327)CAT expression. C, Effect of MafA overexpression on INS(–230)CAT expression. Data for panels B and C are mean ± SEM for three independent experiments.

 
Upstream Regulatory Elements Play a Major Role in Glucose-Mediated Repression of Insulin Promoter Activity
To determine upstream elements involved in glucose repression of insulin promoter activity, a series truncated insulin reporter genes were constructed (Fig. 1AGo). Incubation of INS-1 cells in 16.7 mM glucose for 48 h led to a 79.3 ± 2.2% suppression of INS(–327)CAT expression compared with cells incubated in 4 mM glucose (Fig. 3Go). Deletion of promoter sequences from –327 to –292 [INS(–292)CAT], which removes the A5/core, caused a 2-fold increase in CAT expression in both 4 and 16.7 mM glucose compared with INS(–327)CAT. Removal of these sequences also decreased glucose-mediated suppression of promoter activity to 59.2 ± 3.1%. Deletion of promoter sequences from –327 to –279 [INS(–279)CAT], which removes the A5/core element and destroys a palindrome sequence contained in the Z minienhancer (29) and NRE (30, 31), further reduced the ability of 16.7 mM glucose to suppress insulin promoter (27.9 ± 7.9%). Removal of promoter sequences from –327 to –261 [INS(–261)CAT], which deletes the A5/core element, palindrome element, and the E3 element contained in the NRE and Z minienhancer, did not further reduce the ability of 16.7 mM glucose to suppress insulin promoter activity. Overall, these data indicate that regulatory elements contained between –327 and –261 are involved in glucose-mediated suppression of the insulin promoter activity.



View larger version (14K):
[in this window]
[in a new window]
 
Fig. 3. Upstream Regulatory Elements Play a Major Role in Glucose Repression of Insulin Promoter Activity

INS-1 cells were transiently transfected with 1 µg of INS(–327)CAT, INS(–292)CAT, INS(–279)CAT, INS(–261)CAT, INS(–250)CAT, or INS(–230)CAT and incubated in 4.0 mM or 16.7 mM glucose. Cells were harvested 48 h after transfection, and CAT activity was assayed. CAT activities are reported as the means ± SEM for 10 experiments. *, P < 0.05 for CAT expression in cells treated with 4.0 mM vs. 16.7 mM glucose. See Fig. 1AGo for identification of regulatory elements removed in truncated promoters.

 
Biphasic Regulation of Insulin Promoter Activity by Glucose Involves Sequences Contained within the Z Minienhancer of the Human Insulin Promoter
Sander et al. (29) previously characterized glucose regulation of distal human insulin promoter sequences from –341 to –243 by use of multimerized (five copies) minienhancers linked to the –85 bp minimal promoter from the rat insulin 1 gene promoter. The distal human insulin promoter was divided into X (–342 to –293), Y (–317 to –268), and Z (–292 to –243) minienhancers (Fig. 4AGo). The X and Y minienhancers both contain the A5 element (–319 to –313) and enhancer core element (–313 to –307), whereas the Y minienhancer also contains a palindrome sequence (–284 to –279) (29). The Z minienhancer also contains the palindrome sequence (–284 to –279) and two E box-like sequences separated by 4 bp (–273 to –258) that we have termed the E3a and E3b. The Z minienhancer was further divided into the Za (–292 to –262) and Zb (–274 to –246) minienhancers. The Za minienhancer contains the palindrome sequence (–284 to –279) and the E3a (–273 to –268), whereas the Zb minienhancer contains the E3a and E3b (–273 to –258).



View larger version (20K):
[in this window]
[in a new window]
 
Fig. 4. Biphasic Regulation of Insulin Promoter Activity by Glucose Involves Sequences Contained within the X and Z Minienhancers of the Human Insulin Promoter

A, Schematic representation of insulin promoter elements from –340 to –210 bp. Minienhancers used in multimerized reporter genes as well as electrophoretic mobility shift probes are indicated. INS-1 cells were transiently transfected with CAT reporter genes containing five tandem copies of the Z (panel C) or X (panel D) minienhancer linked to the –85 bp minimal rat l insulin promoter. Cells were also transiently transfected with a CAT reporter gene regulated by the –85 bp minimal rat 1 insulin promoter (pFOXCAT2) as a control (panel B). Cells were then cultured for 48 h in the indicated glucose concentrations, after which cells were harvested and CAT activity was assayed. CAT activity is expressed relative to expression of pFOXCAT2 in cells cultured in 2.0 mM glucose. Values are the mean ± SEM of three independent experiments.

 
To further characterize regions of the distal insulin promoter that are involved in glucose suppression of insulin promoter activity, INS-1 cells were transfected with the various minienhancers and incubated for 48 h in increasing glucose concentrations. The –85 to +1 rat insulin 1 promoter was found to be slightly glucose responsive in INS-1 cells such that there was a 2.7 ± 0.4-fold (P < 0.02) increase in CAT expression in cells incubated in 16.7 mM glucose when compared with 2 mM glucose (Fig. 4BGo). The Z minienhancer was shown to be extremely active in INS-1 cells (Fig. 4CGo) as reported for fetal and adult rat islets (29). As observed for INS(–327)CAT, incubation of INS-1 cells in 6 mM glucose increased Z minienhancer activity 3.1 ± 0.2-fold (P < 0.001) compared with cells incubated in 2 mM glucose. Moreover, incubation of INS-1 cells in media containing 16.7 mM glucose led to a 38.2 ± 5.1% (P < 0.003) reduction in Z minienhancer activity compared with cells incubated in 4 mM glucose. In an attempt to further delineate potential regions within the Z minienhancer that participate in glucose repression of insulin promoter, INS-1 cells were transfected with the Za or Zb minienhancers. Expression of the Za and Zb minienhancers was markedly lower than the Z minienhancer (data not shown). Nevertheless, both the Za and Zb minienhancers exhibited a biphasic response to glucose such that an approximately 4-fold increase in expression was observed in 6 mM glucose, and a strong suppression was observed in 16.7 mM glucose (Table 1Go). These data suggest that the E3a element contained within both the Za and Zb minienhancers may mediate, in part, glucose activation and suppression of the insulin promoter. Alternatively, both the Za and Zb minienhancers may contain independent elements that are glucose responsive.


View this table:
[in this window]
[in a new window]
 
Table 1. Biphasic Regulation of Insulin Promoter Activity Also Involves Sequences Contained within the Y, Za, and Zb Minienhancers of the Human Insulin Gene Promoter

 
In addition to the Z minienhancers, glucose regulation of the FF minienhancer was assessed in INS-1 cells. This minienhancer is under transcriptional regulation of five copies of the rat insulin 1 gene FAR-FLAT elements (37) and the minimal promoter of the rat insulin 1 gene. Importantly, the FAR-FLAT elements are comparable to the human E2-A3 elements that lay outside of the region that primarily accounts for glucose suppression (Fig. 1AGo). In INS-1 cells, increasing glucose concentrations led to increased expression of the FF minienhancer and, unlike the Z minienhancers, was not suppressed at 16.7 mM glucose (Table 1Go). These data strongly demonstrate that glucose suppression of the Z minienhancers is a function of the minienhancer sequences and not a generalized effect. Because Pdx-1 is a primary regulator of the FF minienhancer activity through its interaction at the FLAT region (A3 and A4 elements), this result supports the likelihood that glucose-mediated reductions in Pdx-1 binding activity do not account for loss of promoter activity.

To test for glucose effects on nuclear factor DNA binding activity to elements located in the Z minienhancer, nuclear extracts were made from INS-1 cells grown for 48 h in 4 or 16.7 mM glucose. Because the palindrome sequences (–284 to –279) and the E3a and E3b (–273 to –258) are potential regulatory sites within the Z minienhancer, nuclear factor binding activity to a probe termed Zd (–289 to –253; Fig. 4AGo) was examined by EMSA. As shown in Fig. 5AGo, four specific DNA-protein complexes were observed in cells incubated in either 4 or 16.7 mM glucose. Binding activity of the fastest migrating complex (Zd1) was consistently reduced in cells cultured in 16.7 mM glucose (Fig. 5AGo; compare lanes 2 and 3). In contrast, binding activity of the second fastest migrating complex (Zd2) was consistently induced in cells cultured in 16.7 mM glucose. Competition analysis showed that the slowest migrating complex (Zd4) was effectively competed for by the Za probe (–292 to –263; Fig. 5AGo, lanes 10 and 11) that contains the palindrome and E3a element (Fig. 4AGo). The Zpal probe (–289 to –268), however, was not capable of competing for any of the complexes by itself (Fig. 5AGo, lanes 6 and 7). Competition analysis showed that the E3 probe (–278 to –253; Fig. 5AGo, lanes 8 and 9) could effectively compete for all the Zd binding complexes. The binding activities were not competed by the rat E1 probe (Fig. 5AGo, lanes 12 and 13). DNA-protein complexes similar to that observed for the Zd probe were also observed with an E3 probe (–278 to –253)(Fig. 5BGo). Competition analysis showed that all E3 binding complexes were readily competed by unlabeled E3 probe. When the E3a and E3b sequences were mutated, the E3 probe no longer competed for the binding complexes.



View larger version (74K):
[in this window]
[in a new window]
 
Fig. 5. Elevated Glucose Concentrations Diminish Binding of Nuclear Proteins to the E3 Element Contained within the Z Minienhancer

Nuclear extracts were isolated from INS-1 cells incubated for 48 h in 4.0 or 16.7 mM glucose and tested by EMSA for their ability to bind to DNA probes containing putative regulatory elements found within the Z minienhancer. A, EMSA of 32P-labeled Zd probe. Competition with 100-fold molar excess of unlabeled Zd probe (lanes 4 and 5), Zpal probe (lanes 6 and 7), E3 probe (lanes 8 and 9), Za probe (lanes 10 and 11), and rat insulin E1 probe (lanes 12 and 13). B, EMSA of 32P-labeled E3 probe. Competition with 100-fold molar excess of unlabeled E3 probe (lanes 4 and 5) and mutant E3 probe (mE3, lanes 6 and 7). C, EMSA of 32P-labeled Za probe (lanes 2 and 3) and 32P-labeled Za probes containing mutations at –271 (lanes 4 and 5), –273 (lanes 6 and 7), or –282 and –283 (lanes 8 and 9). EMSA probe sequences and corresponding insulin promoter elements are indicated in Table 3Go and Fig. 4AGo, respectively. Data shown are representative gels of a minimum of three independent experiments. FP, Free probe.

 
Because the Za minienhancer was markedly suppressed in elevated glucose concentrations (Table 1Go) and this minienhancer lacks the E3b element, it was important to determine whether there were any glucose-induced changes in binding activity to the Za minienhancer. As shown in Fig. 5CGo, three specific DNA-protein complexes were observed in nuclear extracts derived from cells incubated in 4 or 16.7 mM glucose. Complex Za2 was markedly reduced in nuclear extracts from cells incubated in 16.7 mM glucose (Fig. 5CGo, lanes 2 and 3). In contrast, complex Za3 was slightly induced. Mutation of bp –271 (T to G), which changes the third base pair of the E3a element, does not affect binding of the three DNA-protein complexes (Fig. 5CGo, lanes 4 and 5). In contrast, mutation of bp –273 (C to G), which changes the first base pair of the E3a element, led to loss of binding of both the Za1 and Za2 complexes (Fig. 5CGo, lanes 6 and 7). Mutation of bp –283 (C to A) and –282 (T to G) contained in the palindrome led to a complete loss in binding of all DNA-protein complexes (Fig. 5CGo, lanes 8 and 9). Overall, these data suggest that both the palindrome and E3a and E3b elements bind nuclear factors that are glucose sensitive.

The X Minienhancer Also Contains Promoter Sequences Involved in Biphasic Regulation of Insulin Promoter Activity by Glucose
Deletion of insulin promoter sequences from –327 to –292 led to a marked reduction in glucose-mediated suppression of insulin promoter activity (Fig. 3Go). This region of the insulin promoter contains the A5 element (–319 to –313) (32), enhancer core element (–313 to –307) (33, 38), and an E box-like element (–300 to –295) that we have termed the E4. To determine the effect of glucose on this general region, INS-1 cells were transfected with the X minienhancer reporter gene (–342 to –292) and incubated for 48 h in increasing glucose concentrations. X minienhancer activity in INS-1 cells was magnitudes lower than that observed for Z minienhancer activity (Fig. 4Go, C and D) as previously observed in fetal rat islets (29). Incubation of INS-1 cells in 6 mM glucose led to a 5.3 ± 0.7-fold (P < 0.01) increase in X minienhancer activity compared with cells cultured in 2 mM glucose (Fig. 4DGo). In contrast, incubation of cells in 16.7 mM glucose led to a 74.4 ± 0.2% (P < 0.01) decrease compared with cells cultured in 4 mM glucose. The Y minienhancer that contains the A5/core, E4, the palindrome, and the E3a elements also demonstrated biphasic regulation by glucose (Table 1Go).

Because the A5, enhancer core element, and E4 are potential regulatory sites within the X and Y minienhancers, nuclear factor binding activity to these elements was examined by EMSA. As shown in Fig. 6AGo, a single slow migrating glucose-sensitive complex bound the A5/core (–323 to –304) probe. This complex was readily competed by excess unlabeled A5/core probe (Fig. 6AGo, lanes 4 and 5). A probe containing three mutations within the overlapping sequences of the A5 element and enhancer core element (CTAATGTG to CTACGTTG) was shown to be ineffective for competition (Fig. 6AGo, lanes 6 and7), thus indicating that this glucose-sensitive complex directly binds the A5 and enhancer core elements. Because the A5 element looks like a Pdx-1 binding site (TCTAATG) and Pdx-1 binding activity has been shown to be glucose sensitive in INS-1 cells (6), it was necessary to determine whether the glucose-sensitive binding complex contained Pdx-1. As shown in Fig. 6BGo, the glucose-sensitive complex was completely competed by unlabeled A5/core probe. In contrast, 100-fold excess of unlabeled A1 or A3 probe, which contain characterized Pdx-1 binding sites, only weakly reduced binding of the glucose-sensitive complex (Fig. 6BGo, lanes 6–9). Addition of anti-N-terminal Pdx-1 antibodies decreased the mobility of the glucose-sensitive complex (Fig. 6CGo, lanes 4 and 5) that recognized the A5/core and decreased the mobility of the Pdx-1 complex that recognizes the human A3 element (Fig. 6CGo, lanes 9 and 10). Binding of the glucose-sensitive complex to the A5/core was not disrupted by the addition of Nkx6.1, Pax6, Isl-1, BMAL1, or p300 antibodies (data not shown). The supershift data demonstrated that the glucose-sensitive complex that recognizes the A5/core contains Pdx-1. Interestingly, this glucose-sensitive complex migrates as a larger Pdx-1 complex than observed on the A3 (Fig. 6CGo) and A1 elements (data not shown). Moreover, the inability of this large complex to be competed for by the A3 and A1 elements suggest that this complex has higher affinity for the A5/core and that the enhancer core sequence stabilizes this interaction. The E4 element contained within the Xa probe bound a specific protein complex that was not glucose responsive (data not shown).



View larger version (66K):
[in this window]
[in a new window]
 
Fig. 6. The A5/Core Binds a Glucose-Sensitive Complex that Contains Pdx-1

Nuclear extracts were isolated from INS-1 cells incubated for 48 h in 4.0 or 16.7 mM glucose and tested by EMSA for their ability to bind the A5/core. A, EMSA using 32P-labeled A5/core (–323/–304). Competition with 100-fold excess of unlabeled A5/core (lanes 4 and 5) or mutated A5/core (mA5/core; lanes 6 and 7) probes. B, EMSA of 32P-labeled A5/core probe. Competition with 100-fold excess unlabeled A5 (lanes 4 and 5), A1 (lanes 6 and 7), or A3 (lanes 8 and 9) probes. Panel E, EMSA using 32P-labeled A5/core (left gel) or A3 (right gel) probes. Anti-Pdx1 antibodies were added to lanes 4, 5, 9, and 10. EMSA probe sequences and corresponding insulin promoter elements are indicated in Table 3Go and Fig. 4AGo, respectively. Data shown are representative gels of a minimum of three independent experiments. FP, Free probe.

 
MafA and, to a Limited Extent, Pdx-1 Stimulate X and Y Minienhancer Activities
The similarity between the A5/core element and other characterized Pdx-1 binding sites suggests that the loss of Pdx-1 binding to the A5/core element accounts for glucose-mediated suppression of both the X and Y minienhancers. Thus, the ability of Pdx-1 or MafA to restore X, Y, or Z minienhancer activity was tested. Overexpression of Pdx-1 led to marked suppression of Z minienhancer activity (Table 2Go). Pdx-1 overexpression also reduced the X and Y minienhancer activity in cells cultured in 4 mM glucose. In cells incubated in 16.7 mM glucose, Pdx-1 increased X minienhancer activity 1.7-fold when compared with cells cultured in 4 mM glucose. As with Pdx-1, overexpression of MafA led to marked suppression of Z minienhancer activity. In contrast, overexpression of MafA led to a strong activation of both the X and Y minienhancers in cells treated with 4 mM glucose, and this was further induced by 16.7 mM glucose. This result was surprising because there are no recognizable MafA consensus sequences [TGCTGAC(G)TCAGCA (39)] found in either the X or Y minienhancers. The similarity in responses between the X and Y minienhancers, however, leaves the possibility that MafA regulates these two minienhancers through a common site such as the A5/core element or E4 element.


View this table:
[in this window]
[in a new window]
 
Table 2. Regulation of X, Y, and Z Minienhancers by MafA or Pdx-1

 
MafA Interacts with the A5/Core Element
Gel mobility shift assays were used to determine whether the glucose-sensitive complex that interacts with the A5/core element contains MafA. Exposure of INS-1 cells to elevated glucose led to the loss of binding activity to the A5/core probe (Fig. 7Go, A and B; lanes 2 and 3). The glucose-sensitive binding activity was effectively competed for with a 100-fold excess of unlabeled A2-C1 probe (Fig. 7AGo, lanes 4 and 5). MafA antibodies consistently decreased the mobility of the glucose-sensitive complex; however, due to the size of the complex, it was not always effectively resolved by EMSA (Fig. 7BGo, lanes 4 and 5). MafA antibodies were also shown to effectively supershift the glucose-sensitive complex that recognizes the A2-C1 probe (Fig. 7BGo, lanes 9 and 10). These data indicate that the large glucose-sensitive binding complex that recognizes the A5/core contains MafA. Surprisingly, the glucose-sensitive binding complex was also effectively competed by an unlabeled probe containing a mutated C1 element (A2-mC1) that disrupts the MafA binding site (Fig. 7AGo, lanes 6 and 7). The enhancer core and A2 element do, however, share a common sequence (TGGAAAXTG; see Table 3Go) suggesting that these elements bind a common factor. Mutation of the A2 element at –122/–121 (TGGACCCT) was previously shown by Harrington and Sharma (40) to effectively prevent A2 factor binding. Probes containing a mutated A2 element in the context of a wild-type or mutated C1 element (mA2-C1 or mA2-mC1) were tested for the ability to compete for the A5/core binding complex. Addition of 100-fold excess of mA2-C1 or mA2-mC1 probes was unable to compete for the glucose-sensitive binding complex that recognizes the A5/core (Fig. 7AGo, lanes 8 to 11). Overall, these data suggest that the glucose-sensitive A5/core complex contains Pdx-1, MafA, and an A2 binding factor.



View larger version (57K):
[in this window]
[in a new window]
 
Fig. 7. The Glucose-Responsive A5/Core Binding Complex Contains MafA

Nuclear extracts were isolated from INS-1 cells incubated in 48 h in 4 or 16.7 mM glucose. Panel A, EMSA using 32P-labeled A5/core probe. Competition using 100-fold excess of unlabeled A2-C1 (lanes 4 and 5), A2 mutated-C1 (A2mC1, lanes 6 and 7), mutated-A2 C1 (mA2C1, lanes 8 and 9), and mutated-A2 mutated-C1 (mA2mC1, lanes 10 and 11) probes. B, EMSA using 32P-labeled A5/core probe (left) or 32P-labeled rat insulin gene A2-C1 probe (right). Anti-MafA antibodies were added to lanes 4, 5, 9, and 10. EMSA probe sequences and corresponding insulin promoter elements are indicated in Table 3Go and Fig. 4AGo, respectively. EMSA is a representative gel of three independent experiments. Asterisk indicates glucose-sensitive A5/core binding complex. C1 indicates glucose-sensitive A2C1 binding complex. Unlabeled arrow marks the A2C1 complex supershifted with MafA antibodies. FP, Free probe.

 

View this table:
[in this window]
[in a new window]
 
Table 3. Oligodeoxynucleotide Sequences Used in EMSAs

 
Mutation of the A5/Core, Palindrome, and E3 Elements Partially Diminishes Glucose-Mediated Suppression of Insulin Promoter Activity
To investigate the involvement of the A5/core, the palindrome, and/or the E3 element in glucose-mediated suppression of the insulin promoter, these elements were mutated separately or in combination in the context of the INS(–323)CAT reporter gene. As previously shown, incubation of INS-1 cells in high glucose concentration led to a 86.6% suppression in INS(–327)CAT expression compared with cells incubated in low glucose (Table 4Go). Mutation of the palindrome [mZpal(–323)CAT] increased insulin promoter activity but only had a minor affect on glucose-mediated suppression of insulin promoter activity. Combined mutations of the palindrome and A5/core [mA5/core/Zpal(–323)CAT] or E3 [mZpal/E3(–323)CAT] elements led to further reductions in promoter activity and diminished glucose-mediated suppression of promoter activity. Combined mutation of the A5/core, palindrome, and E3 [mA5/core/Zpal/E3(–323)CAT] markedly lowered promoter activity and further diminished glucose-mediated suppression of insulin promoter activity. These data support the hypothesis that alterations in binding activities to these elements may be sufficient to account for the large reduction in insulin promoter activity observed in high glucose.


View this table:
[in this window]
[in a new window]
 
Table 4. Mutation of the A5/Core, Z Palindrome, and E3 Elements Partially Attenuate Glucose-Induced Suppression of Insulin Promoter Activity

 

    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 
In a number of in vitro and in vivo models, prolonged exposure of pancreatic ß-cells to hyperglycemia leads to reduced insulin gene expression. Studies employing HIT-T15, ßTC3, and INS-1 cells have shown that the reduction in insulin gene expression results from reduced insulin promoter activity that occurs with a commensurate reduction in expression and/or binding of Pdx-1 and the C1 activator (5, 6, 13, 15) and increased expression of C/EBPß (19). In a similar manner, chronic hyperglycemia induced after partial pancreatectomy in rats reduced insulin gene expression, and this correlated with decreased expression of Pdx-1 (7, 8, 11) and enhanced expression of C/EBPß (8) and c-Myc (11). Enhanced c-Myc expression has also been reported to occur in rats infused with glucose for 1–4 d and in isolated rat islets incubated in elevated glucose for 18 h (20). In Zucker diabetic fatty (fa/fa) rats, a model of chronic hyperglycemia and hyperlipidemia, insulin and Pdx-1 mRNA and protein are reduced (8, 9) whereas C/EBPß protein and mRNA levels are increased (8). Prevention of hyperglycemia or oxidative stress in Zucker diabetic fatty (fa/fa) rats helped to preserve insulin gene expression and Pdx-1 binding activity (9, 10, 41).

Although the above studies suggest that prolonged elevations of glucose reduce insulin gene expression, in part, by reducing Pdx-1 levels, no direct correlation has been established. For example, expression of Pdx-1 in INS-1 cells exposed to elevated glucose concentrations did not prevent the reduction in –327 insulin promoter activity. In fact, overexpression of Pdx-1 in INS-1 cells cultured in 4 mM glucose suppressed the –327 insulin promoter activity (data not shown) as previously reported for RIN 1046-36 cells (42). Moreover, expression of Pdx-1 in late-passage HIT-T15 cells, which have markedly reduced insulin promoter activity and Pdx-1 levels, does not restore promoter activity to levels observed in early passages of HIT-T15 cells (18). The possibility that reduced Pdx-1 levels do not account for glucose-mediated suppression in insulin promoter activity is further exemplified by the observation that antisense Pdx-1 RNA can lower Pdx-1 protein levels in MIN6 or ßTC1 cells without affecting insulin mRNA levels (43). Consistent with this observation, mice containing only one functional allele for Pdx-1 have reduced Pdx-1 protein levels but normal pancreatic insulin content (44).

As described above, loss of C1 activator binding is also associated with glucose suppression of insulin promoter activity. Supershift analysis indicated that the C1 activator complex that has reduced binding in INS-1 cells cultured in elevated glucose contains MafA. Overexpression of MafA in INS-1 cells cultured in 16.7 mM glucose increased –327 insulin promoter activity above the level observed in 4 mM glucose. These data can be interpreted in two ways: either loss of MafA binding accounts for loss of insulin promoter activity, or that MafA acting as a strong transcriptional activator overrides the suppression by glucose independent of being the mechanism of action. The latter possibility is supported by the observation that MafA activates a truncated insulin promoter (–230) that is only modestly repressed by glucose, and that MafA is strongly activated by glucose (16). Nevertheless, in HIT-T15 and ßTC6 cells chronically exposed to elevated glucose, the timing for loss of insulin promoter activity coincides best with diminished C1 activator and not loss of Pdx-1 binding (5, 18). Moreover, in INS-1 cells, elevated glucose diminishes MafA binding to a greater extent than Pdx-1 binding (6).

Truncation analysis of the human insulin gene promoter indicated that the majority of glucose-mediated suppression in INS-1 cells occurs between sequences –327 to –261. Contained within these sequences is a previously described glucose-responsive region (the Z element, –292 to –243) that is extremely active in primary islet cells (28, 29) and serves as an NRE in SV40 or T antigen immortalized ß cell lines (29, 30, 31). Promoter deletions that remove the Z element have been reported to reduce promoter activity in primary islet cells (28), whereas similar deletions increased insulin promoter activity in HIT M2.2.2 cells (30). The Z minienhancer was previously shown to be very active in primary islet cells, but suppressed in SV40 or T antigen immortalized ß-cell lines (29). Suppression of the Z minienhancer in these immortalized ß-cell lines appears related to elevated cell proliferation because Z minienhancer activity was also extremely low in proliferating fibroblasts (29). As reported for primary islet cells, we have found that the Z minienhancer was extremely active in INS-1 cells and that deletion of the Z element markedly reduced insulin promoter activity. These data suggest that under low glucose concentrations (2–8 mM) INS-1 cells regulate the human insulin promoter in a manner more similar to primary islet cells than to SV40 or T antigen immortalized ß-cell lines. Under elevated glucose, the Z minienhancer was suppressed and this may be due, in part, to increased INS-1 cell proliferation (6, 45, 46). Understanding the relationship between ß-cell proliferation and suppression of the Z minienhancer is important because in vitro expansion of human ß-cells is generally associated with down-regulated insulin gene expression that can occur without the loss of Pdx-1 (47, 48). Prevention of INS-1 cell proliferation, however, is not sufficient to block glucose-mediated suppression of insulin mRNA expression or promoter activity (Ref.6 and data not shown), strongly suggesting that more than one molecular mechanism is involved.

To explore possible mechanisms for glucose-mediated suppression of the Z-minienhancer in INS-1 cells, we characterized potential regulatory sites for changes in binding activity. Within the Z element, we identified two putative regulatory elements, E3 element and a palindrome, that demonstrated altered binding activity in response to elevated glucose. The E3 element is composed of two putative E boxes (CANNTG), E3a and E3b, separated by 4 bp. Gel shift analysis using a probe (Zd) that spanned the E3 element and the palindrome identified four specific binding complexes. Of interest, the Zd1 binding complex was partly reduced, whereas the Zd2 complex was partly increased, in nuclear extracts derived from INS-1 cells cultured in elevated glucose. Similar binding complexes were also observed with a gel shift probe that contained only the E3 element, and competition analysis demonstrated that binding required intact E box sequences. Although the identity of these factors is unknown, we postulate that these changes in binding activity may represent the loss of activator binding and subsequent binding of a transcriptional repressor. Transcriptional repression of the insulin promoter by c-myc or C/EBPß has been reported to occur through E boxes such as the insulin promoter E1 element (19, 49).

Gel shift analysis of a probe (Za) that spanned the palindrome and the E3a element identified three specific binding complexes of which the Za2 complex was markedly reduced in nuclear extracts derived from INS-1 cells cultured in elevated glucose. We found that binding of the glucose-sensitive complex was abolished when the first base pair (–273) of the E3a element was mutated. In contrast, binding of the glucose-sensitive complex was preserved when the third base pair (–271) of the E3a element was mutated. These results are important because the glucose-responsive Za binding complex identified in rat fetal islet (ZaI) by Sander et al. (29) did not require the base pair located at –271 for binding. Equally important, mutation of bp –271 completely prevented binding of a complex found in ßTC3 and HIT M2.2.2 cells (29, 31) and eliminated repressor activity present in HIT M2.2.2 cells (31). In contrast, mutation of bp –272 and bp –273 did not prevent repressor binding or activity present in HIT M2.2.2 cells (31). Therefore, our results suggest that the Za2 binding activity present in INS-1 cells is distinct from the Za binding activity or transcriptional repressor found in ßTC3 or HIT M.2.2.2 cells. The relationship between the glucose-responsive Za binding complex identified in INS-1 cells and fetal rat islets is uncertain. Binding of the Za complex in INS-1 cells was completely prevented when sequences within the palindrome (–283/–282) were mutated. In contrast, Sander et al. (29) reported that the glucose-responsive Za complex in rat fetal islets (ZaI) was effectively competed by 150-fold excess of a mutated –283/–282 Za probe. Studies designed to determine the relationship between the Za complexes in INS-1 cells and rat islets are ongoing.

Changes in binding activities to both the E3 and palindrome likely contribute to glucose suppression of Z element activity. This is supported by the observation that both the Za minienhancer, which contains the palindrome and E3a, and the Zb minienhancer, which contains the intact E3, are suppressed by elevated glucose. As reported for primary islet cells (29), activities of the Za and Zb minienhancers in INS-1 cells were many magnitudes lower than the activity of the Z minienhancer. These data suggest that the Za minienhancer requires adjacent elements contained within the Zb minienhancer to confer full activity to the Z minienhancer as proposed by Sander et al. (29). This also implies that glucose-mediated changes in binding activity to either the E3 or palindrome could markedly impact synergistic interactions necessary for full Z minienhancer activity. Such synergistic interactions are well documented for the rat insulin 1 promoter in which the E2/A3/A4 minienhancer functions as an independent glucose-regulated transcriptional unit (50, 51).

The X and Y minienhancers were also found to be activated by increasing glucose concentrations from 2–8 mM and to be suppressed by higher glucose concentrations. This observation is in contrast to that of Sander et al. (29), who described these minienhancers to be unresponsive to changes in glucose concentration in primary islet cells. Three potential regulatory elements, including the A5, enhancer core, and E4, are common between the X and Y minienhancers. The A5 element is present only in the human insulin gene promoter and overlaps the enhancer core. The enhancer core is highly conserved and shown to bind a ß-cell-enriched nuclear factor complex (33). We found that binding to the A5/core was markedly reduced in nuclear extracts isolated from INS-1 cells incubated in high glucose concentrations, whereas binding to the E4 element was unaffected by glucose. Because the A5 element contains a sequence similar to the A3 element, a well-defined Pdx-1 binding site (TCTAATG), we predicted that the glucose-responsive binding activity would contain Pdx-1. Surprisingly, we found that the glucose-responsive binding activity migrated much slower than the Pdx-1 complex that forms on either the A3 or A1 elements, and was poorly competed by A3 or A1 elements. The glucose-sensitive complex, however, was determined to contain Pdx-1 by supershift analysis using specific antibodies against Pdx-1. These data suggest that Pdx-1, along with factors that possibly interact with the enhancer core, forms a high-affinity binding complex. Consistent with the observation that Pdx-1 binds the A5 element, overexpression of Pdx-1 led to a small increase in expression of both the X and Y minienhancers in cells cultured in elevated glucose.

Overexpression of MafA led to a large glucose-dependent activation of both the X and Y minienhancers. This was surprising because we were unable to identify any consensus MafA binding sites [TGCTGAC(G)TCAGCA (39)] within either minienhancer. The enhancer core element (TGGAAAGTG), however, resembles the A2 element (TGGAAACTG) that, together with the C1 element, serves as the binding site for RIPE3b1 (MafA) (40). Consistent with this observation, the A2 element, independent of the C1, effectively competed for the glucose-sensitive A5/core binding complex. Existence of MafA within the A5/core complex was demonstrated by supershift analysis. Based on these results, we propose that the A5/core binding activity is a large complex comprised of Pdx-1 binding to the A5 element and an A2 binding factor that interacts with the enhancer core. The identity of the A2 binding factor is unknown; however, nuclear factor of activated T cells (NFAT) has been identified in INS-1 and can bind both the A2 and enhancer core (52). The juxtaposition between Pdx-1 and the A2 factor stabilizes the complex and leads to the recruitment of MafA possibly independent of a consensus MafA binding site. Such interactions are supported by the observation that the homeodomain of Pdx-1 can interact with a number of transcription factors including E47/Pan1 and HMG I(Y) (53), whereas the Pdx-1 homeodomain plus adjacent FPWMK peptide interacts with Pbx1 (54). Interactions between Pdx-1 and Pbx1 have been shown to change the specificity of Pdx-1 binding such that Pdx-1 and Pbx1 cooperatively bind to the somatostatin promoter, but not to the A3/A4 elements of the rat 1 insulin promoter (54). The interaction of Pdx-1, A2 factor, and MafA through the A5/core element and its possible involvement in regulation of human insulin promoter activity by glucose warrant further investigation.

In conclusion, our data indicate that exposure of INS-1 cells to elevated glucose suppresses human insulin promoter activity primarily through the Z element and A5/core element. The relevance of these observations for primary ß-cells is indicated by the bell-shaped curve of glucose stimulation of insulin promoter activity in isolated rat islets (Fig. 1DGo) after 24 h of exposure. This is further exemplified by the large, yet reversible, suppression of insulin promoter activity that occurs when human islets are exposed to elevated glucose concentrations for 4–9 d (14). Understanding how elevated glucose causes these changes in binding activity to occur and proteins involved may provide insights into how elevations in glucose affect gene expression in pancreatic ß-cells and may provide valuable insight into engineering of ß-cells that express high levels of insulin that can be positively regulated in a glucose-dependent manner.


    MATERIALS AND METHODS
 TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 
Materials
Cell culture media and Lipofectamine were purchased from Invitrogen (Carlsbad, CA). [{alpha}-32P]dCTP, [{gamma}-32P]ATP, and [14C]chloramphenicol were from PerkinElmer Life Sciences (Boston, MA). pFOXCAT.RIP1, pFOXCAT.RIP1.5xX, pFOXCAT.RIP1.5xZ, pFOXCAT.RIP1.5xZa, pFOXCAT.RIP1.5xZb, pFOXCAT.RIP1.5xY (29), and anti-Nkx6.1 antibodies were received from Dr. M. German (University of California, San Francisco, CA). Anti-Pdx-1 antibodies were received from Dr. C. Wright (Vanderbilt University, Nashville, TN). Anti-Isl-1 (39.4D5) and anti-Pax6 monoclonal antibodies were received from the Developmental Studies Hybridoma Bank (University of Iowa, Iowa City, IA). Anti-BMAL1 and p300 (N-15) antibodies were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Anti-MafA antibodies (BL1069) were from Bethyl Laboratories (Montgomery, TX).

INS-1 Cell Culture
INS-1 cells [from Dr. C. Wollheim (55)] were routinely cultured in 5% CO2-95% air at 37 C in RPMI 1640 media containing 11.1 mM glucose and supplemented with 10% fetal bovine serum (FBS), 1 mM pyruvate, 10 mM HEPES, 50 µM 2-mercaptoethanol, 100 U/ml penicillin, and 100 µg/ml streptomycin. Cells were passed weekly after trypsin-EDTA detachment. All experiments were performed on INS-1 cells between passages 70 and 80.

Reporter Gene Studies
The plasmid INS(–327)CAT contains the chloramphenicol acetyltransferase (CAT) gene under transcriptional regulation by the human insulin gene sequences –327 to +30 as previously described (4). Insulin reporter genes containing 5'-truncations (Fig. 3AGo) were constructed by PCR amplification using INS(–327)CAT as the template and oligodeoxynucleotide primers listed in Table 5Go. Site-specific mutations were generated by PCR amplification using derivatives of INS(–327)CAT or INS(–230)CAT and oligodeoxynucleotide primers listed in Table 5Go. All plasmid sequences were verified by sequencing on an ABI Prism 3700 DNA Analyzer (Applied Biosystems, Foster City, CA). Multiple preparations of each plasmid were used in all experiments to assure that changes in reporter gene activities were due to specific deletions and/or mutations.


View this table:
[in this window]
[in a new window]
 
Table 5. Oligodeoxynucleotide Sequences Used for Construction of Human Insulin Reporter Genes

 
For all reporter gene studies, INS-1 cells were subcultured for 2 d before transfection at a density of 1.5 x 106 cells per well (diameter, 3.5 cm) in RPMI 1640 media supplemented as described above. INS-1 cells were transfected for 5 h as previously described (6) using a ratio of 1 µg plasmid to 2 µl Lipofectamine and then incubated in RPMI 1640 media supplemented as described above and the indicated glucose concentration (see figure legends). Cells were harvested 48 h after transfection, and CAT activities were assayed.

Pdx-1 and MafA Expression Constructs
Rat Pdx-1 or MafA was subcloned downstream of the CMV enhancer contained within the pCR3.1 expression vector. Sequences were verified on an ABI Prism 3700 DNA Analyzer.

Recombinant Adenoviruses
The recombinant adenovirus, Ad-RIP1-Luc, contains the luciferase reporter gene under the transcriptional control of the rat 1 insulin gene promoter sequences –310 to –12 as previously described (56). The control adenovirus, Ad-CMV-Luc, contains the luciferase reporter gene under the transcriptional control of the CMV promoter (57).

Rat Islet Isolation, Culture, and Infection with Recombinant Adenoviruses
Rat islets were isolated and purified as previously described (58). Duplicate batches of 100 islets were each infected overnight with 107 plaque-forming units per islet of Ad-RIP1-Luc or Ad-CMV-Luc in RPMI 1640 containing 10% FBS, 100 U/ml penicillin, 100 µg/ml streptomycin, and 11.1 mM glucose. Islets were then incubated for 8 h in RPMI 1640 containing 10% FBS and 2.8 mM glucose. Islets were then incubated for 24 h in RPMI 1640 containing 0.1% BSA and various glucose concentrations (see figure legends). Luciferase activity in islet extracts was measured using the Luciferase Assay kit (Promega Corp., Madison, WI) according to manufacturer’s directions.

Nuclear Extracts and EMSAs
Nuclear extracts were made from INS-1 cells according to the method of Schreiber et al. (59). Double-stranded oligodeoxynucleotide probes (for sequences, see Table 3Go) were labeled with [{alpha}-32P]dCTP by filling in overhanging 5'-ends with the large fragment of DNA polymerase 1 or were labeled with [{gamma}-32P]ATP and T4 polynucleotide kinase. Binding reactions (10 µg protein per lane) and electrophoresis conditions were performed as described by Shih and Towle (60). Competition analyses were performed using 50- to 100-fold molar excess of unlabeled double-stranded oligodeoxynucleotides (for sequences, see Table 3Go). Supershift analyses were generally performed by use of 1 or 2 µl antibodies. MafA supershift analyses, however, were performed by use of 4–5 µg of anti-MafA antibodies as recommended by the manufacturer.

Data Presentation and Statistical Analysis
Reporter gene data are presented as means ± SEM. Comparisons were performed by unpaired Student’s t test; P < 0.05 was considered significant.


    ACKNOWLEDGMENTS
 
The PAX6 monoclonal antibody developed by Briscoe and colleagues (61 ) and the Isl-1 monoclonal antibody developed by Ericson et al. (62 ) were obtained from the Developmental Studies Hybridoma Bank developed under the auspices of the National Institute of Child Health and Human Development and maintained by the University of Iowa, Department of Biological Sciences (Iowa City, IA). We thank Dr. Michael German and Dr. Chris Wright for providing the minienhancer reporter genes and the anti-N-terminal Pdx-1 antibodies, respectively.


    FOOTNOTES
 
This work was supported by grants from the American Diabetes Association (to L.K.O), Michigan Life Science Corridor Grants GR178 and GR352 (to L.K.O.), and by National Institutes of Health Grant R01-DK58096 (to V.P.).

Present address for M.F.P.: Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, Tennessee 37232.

First Published Online January 13, 2005

1 M.F.P. and D.Z.Y. contributed equally to this work. Back

Abbreviations: CAT, Chloramphenicol acetyltransferase; C/EBPß, CAAT/enhancer binding protein ß; CMV, cytomegalovirus; FBS, fetal bovine serum; NRE, negative regulatory element; Pdx-1, pancreatic duodenal homeobox factor 1; SV40, simian virus 40.

Received for publication December 23, 2003. Accepted for publication January 4, 2005.


    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 

  1. Laybutt DR, Sharma A, Sgroi DC, Gaudet J, Bonner-Weir S, Weir GC 2002 Genetic regulation of metabolic pathways in ß-cells disrupted by hyperglycemia. J Biol Chem 277:10912–10921[Abstract/Free Full Text]
  2. Laybutt DR, Kaneto H, Hasenkamp W, Grey S, Jonas JC, Sgroi DC, Groff A, Ferran C, Bonner-Weir S, Sharma A, Weir GC 2002 Increased expression of antioxidant and antiapoptotic genes in islets that may contribute to ß-cell survival during chronic hyperglycemia. Diabetes 51:413–423[Abstract/Free Full Text]
  3. Efanova IB, Zaitsev SV, Zhivotovsky B, Kohler M, Efendic S, Orrenius S, Berggren PO 1998 Glucose and tolbutamide induce apoptosis in pancreatic ß-cells. A process dependent on intracellular Ca2+ concentration. J Biol Chem 273:33501–33507[Abstract/Free Full Text]
  4. Olson LK, Redmon JB, Towle HC, Robertson RP 1993 Chronic exposure of HIT cells to high glucose concentrations paradoxically decreases insulin gene transcription and alters binding of insulin gene regulatory protein. J Clin Invest 92:514–519[Medline]
  5. Poitout V, Olson LK, Robertson RP 1996 Chronic exposure of ßTC-6 cells to supraphysiologic concentrations of glucose decreases binding of the RIPE3b1 insulin gene transcription activator. J Clin Invest 97:1041–1046[Abstract/Free Full Text]
  6. Olson L, Qian J, Poitout V 1998 Glucose rapidly and reversibly decreases INS-1 cell insulin gene transcription via decrements in STF-1 and C1 activator transcription factor activity. Mol Endocrinol 12:207–219[Abstract/Free Full Text]
  7. Zangen DH, Bonner-Weir S, Lee CH, Latimer JB, Miller CP, Habener JF, Weir GC 1997 Reduced insulin, GLUT2, and IDX-1 in ß-cells after partial pancreatectomy. Diabetes 46:258–264[Abstract]
  8. Seufert J, Weir GC, Habener JF 1998 Differential expression of the insulin gene transcriptional repressor CCAAT/enhancer-binding protein ß and transactivator islet duodenum homeobox-1 in rat pancreatic ß cells during the development of diabetes mellitus. J Clin Invest 101:2528–2539[Abstract/Free Full Text]
  9. Harmon JS, Gleason CE, Tanaka Y, Oseid EA, Hunter-Berger KK, Robertson RP 1999 In vivo prevention of hyperglycemia also prevents glucotoxic effects on PDX-1 and insulin gene expression. Diabetes 48:1995–2000[Abstract]
  10. Tanaka Y, Gleason CE, Tran PO, Harmon JS, Robertson RP 1999 Prevention of glucose toxicity in HIT-T15 cells and Zucker diabetic fatty rats by antioxidants. Proc Natl Acad Sci USA 96:10857–10862[Abstract/Free Full Text]
  11. Jonas JC, Sharma A, Hasenkamp W, Ilkova H, Patane G, Laybutt R, Bonner-Weir S, Weir GC 1999 Chronic hyperglycemia triggers loss of pancreatic ß cell differentiation in an animal model of diabetes. J Biol Chem 274:14112–14121[Abstract/Free Full Text]
  12. Leibowitz G, Ferber S, Apelqvist A, Edlund H, Gross DJ, Cerasi E, Melloul D, Kaiser N 2001 IPF1/PDX1 deficiency and ß-cell dysfunction in Psammomys obesus, an animal with type 2 diabetes. Diabetes 50:1799–1806[Abstract/Free Full Text]
  13. Sharma A, Olson LK, Robertson RP, Stein R 1995 The reduction of insulin gene transcription in HIT-T15 ß cells chronically exposed to high glucose concentration is associated with the loss of RIPE3b1 and STF-1 transcription factor expression. Mol Endocrinol 9:1127–1134[Abstract]
  14. Marshak S, Leibowitz G, Bertuzzi F, Socci C, Kaiser N, Gross DJ, Cerasi E, Melloul D 1999 Impaired ß-cell functions induced by chronic exposure of cultured human pancreatic islets to high glucose. Diabetes 48:1230–1236[Abstract]
  15. Olson LK, Sharma A, Peshavaria M, Wright CV, Towle HC, Robertson RP, Stein R 1995 Reduction of insulin gene transcription in HIT-T15 ß cells chronically exposed to a supraphysiologic glucose concentration is associated with loss of STF-1 transcription factor expression. Proc Natl Acad Sci USA 92:9127–9131[Abstract/Free Full Text]
  16. Kataoka K, Han SI, Shioda S, Hirai M, Nishizawa M, Handa H 2002 MafA is a glucose-regulated and pancreatic ß-cell-specific transcriptional activator for the insulin gene. J Biol Chem 277:49903–49910[Abstract/Free Full Text]
  17. Olbrot M, Rud J, Moss LG, Sharma A 2002 Identification of ß-cell-specific insulin gene transcription factor RIPE3b1 as mammalian MafA. Proc Natl Acad Sci USA 99:6737–6742[Abstract/Free Full Text]
  18. Harmon JS, Tanaka Y, Olson LK, Robertson RP 1998 Reconstitution of glucotoxic HIT-T15 cells with somatostatin transcription factor-1 partially restores insulin promoter activity. Diabetes 47:900–904[Abstract]
  19. Lu M, Seufert J, Habener JF 1997 Pancreatic ß-cell-specific repression of insulin gene transcription by CCAAT/enhancer-binding protein ß. Inhibitory interactions with basic helix-loop-helix transcription factor E47. J Biol Chem 272:28349–28359[Abstract/Free Full Text]
  20. Jonas JC, Laybutt DR, Steil GM, Trivedi N, Pertusa JG, Van de Casteele M, Weir GC, Henquin JC 2001 High glucose stimulates early response gene c-Myc expression in rat pancreatic ß cells. J Biol Chem 276:35375–35381[Abstract/Free Full Text]
  21. Jonsson J, Carlsson L, Edlund T, Edlund H 1994 Insulin-promoter-factor 1 is required for pancreas development in mice. Nature 371:606–609[CrossRef][Medline]
  22. Jonsson J, Ahlgren U, Edlund T, Edlund H 1995 IPF1, a homeodomain protein with a dual function in pancreas development. Int J Dev Biol 39:789–798[Medline]
  23. Offield MF, Jetton TL, Labosky PA, Ray M, Stein RW, Magnuson MA, Hogan BL, Wright CV 1996 PDX-1 is required for pancreatic outgrowth and differentiation of the rostral duodenum. Development 122:983–995[Abstract/Free Full Text]
  24. Ahlgren U, Jonsson J, Jonsson L, Simu K, Edlund H 1998 ß-Cell-specific inactivation of the mouse Ipf1/Pdx1 gene results in loss of the ß-cell phenotype and maturity onset diabetes. Genes Dev 12:1763–1768[Abstract/Free Full Text]
  25. Wang H, Maechler P, Ritz-Laser B, Hagenfeldt KA, Ishihara H, Philippe J, Wollheim CB 2001 Pdx1 level defines pancreatic gene expression pattern and cell lineage differentiation. J Biol Chem 276:25279–25286[Abstract/Free Full Text]
  26. Waeber G, Thompson N, Nicod P, Bonny C 1996 Transcriptional activation of the GLUT2 gene by the IPF-1/STF-1/IDX-1 homeobox factor. Mol Endocrinol 10:1327–1334[Abstract]
  27. Watada H, Kajimoto Y, Miyagawa J, Hanafusa T, Hamaguchi K, Matsuoka T, Yamamoto K, Matsuzawa Y, Kawamori R, Yamasaki Y 1996 PDX-1 induces insulin and glucokinase gene expressions in {alpha}TC1 clone 6 cells in the presence of betacellulin. Diabetes 45:1826–1831[Abstract]
  28. Odagiri H, Wang J, German MS 1996 Function of the human insulin promoter in primary cultured islet cells. J Biol Chem 271:1909–1915[Abstract/Free Full Text]
  29. Sander M, Griffen SC, Huang J, German MS 1998 A novel glucose-responsive element in the human insulin gene functions uniquely in primary cultured islets. Proc Natl Acad Sci USA 95:11572–11577[Abstract/Free Full Text]
  30. Boam DS, Clark AR, Docherty K 1990 Positive and negative regulation of the human insulin gene by multiple trans-acting factors. J Biol Chem 265:8285–8296[Abstract/Free Full Text]
  31. Clark AR, Wilson ME, Leibiger I, Scott V, Docherty K 1995 A silencer and an adjacent positive element interact to modulate the activity of the human insulin promoter. Eur J Biochem 232:627–632[Abstract]
  32. German M, Ashcroft S, Docherty K, Edlund H, Edlund T, Goodison S, Imura H, Kennedy G, Madsen O, Melloul D, Moss L, Olson K, Permutt MA, Philippe J, Robertson RP, Rutter WJ, Serup P, Stein R, Steiner D, Tsai M-J, Walker MD 1995 The insulin gene promoter. A simplified nomenclature. Diabetes 44:1002–1004[Medline]
  33. Ohlsson H, Edlund T 1986 Sequence-specific interactions of nuclear factors with the insulin gene enhancer. Cell 45:35–44[CrossRef][Medline]
  34. Sander M, German MS 1997 The ß cell transcription factors and development of the pancreas. J Mol Med 75:327–340[CrossRef][Medline]
  35. Ohlsson H, Karlsson K, Edlund T 1993 IPF1, a homeodomain-containing transactivator of the insulin gene. EMBO J 12:4251–4259[Abstract]
  36. Naya FJ, Stellrecht CM, Tsai MJ 1995 Tissue-specific regulation of the insulin gene by a novel basic helix-loop-helix transcription factor. Genes Dev 9:1009–1019[Abstract]
  37. German MS, Wang J 1994 The insulin gene contains multiple transcriptional elements that respond to glucose. Mol Cell Biol 14:4067–4075[Abstract]
  38. Moss LG, Moss JB, Rutter WJ 1988 Systematic binding analysis of the insulin gene transcription control region: insulin and immunoglobulin enhancers utilize similar transactivators. Mol Cell Biol 8:2620–2627[Medline]
  39. Matsuoka TA, Artner I, Henderson E, Means A, Sander M, Stein R 2004 The MafA transcription factor appears to be responsible for tissue-specific expression of insulin. Proc Natl Acad Sci USA 101:2930–2933[Abstract/Free Full Text]
  40. Harrington RH, Sharma A 2001 Transcription factors recognizing overlapping C1–A2 binding sites positively regulate insulin gene expression. J Biol Chem 276:104–113[Abstract/Free Full Text]
  41. Harmon JS, Gleason CE, Tanaka Y, Poitout V, Robertson RP 2001 Antecedent hyperglycemia, not hyperlipidemia, is associated with increased islet triacylglycerol content and decreased insulin gene mRNA level in Zucker diabetic fatty rats. Diabetes 50:2481–2486[Abstract/Free Full Text]
  42. Seijffers R, Ben-David O, Cohen Y, Karasik A, Berezin M, Newgard CB, Ferber S 1999 Increase in PDX-1 levels suppresses insulin gene expression in RIN 1046–38 cells. Endocrinology 140:3311–3317[Abstract/Free Full Text]
  43. Kajimoto Y, Watada H, Matsuoka T, Kaneto H, Fujitani Y, Miyazaki J, Yamasaki Y 1997 Suppression of transcription factor PDX-1/IPF1/STF-1/IDX-1 causes no decrease in insulin mRNA in MIN6 cells. J Clin Invest 100:1840–1846[Abstract/Free Full Text]
  44. Brissova M, Shiota M, Nicholson WE, Gannon M, Knobel SM, Piston DW, Wright CV, Powers AC 2002 Reduction in pancreatic transcription factor PDX-1 impairs glucose-stimulated insulin secretion. J Biol Chem 277:11225–11232[Abstract/Free Full Text]
  45. Hugl SR, White MF, Rhodes CJ 1998 Insulin-like growth factor I (IGF-I)-stimulated pancreatic ß-cell growth is glucose-dependent. Synergistic activation of insulin receptor substrate-mediated signal transduction pathways by glucose and IGF-I in INS-1 cells. J Biol Chem 273:17771–17779[Abstract/Free Full Text]
  46. Cousin SP, Hugl SR, Myers Jr MG, White MF, Reifel-Miller A, Rhodes CJ 1999 Stimulation of pancreatic ß-cell proliferation by growth hormone is glucose-dependent: signal transduction via janus kinase 2 (JAK2)/signal transducer and activator of transcription 5 (STAT5) with no crosstalk to insulin receptor substrate-mediated mitogenic signalling. Biochem J 344:649–658[CrossRef][Medline]
  47. Beattie GM, Rubin JS, Mally MI, Otonkoski T, Hayek A 1996 Regulation of proliferation and differentiation of human fetal pancreatic islet cells by extracellular matrix, hepatocyte growth factor, and cell-cell contact. Diabetes 45:1223–1228[Abstract]
  48. Beattie GM, Itkin-Ansari P, Cirulli V, Leibowitz G, Lopez AD, Bossie S, Mally MI, Levine F, Hayek A 1999 Sustained proliferation of PDX-1+ cells derived from human islets. Diabetes 48:1013–1019[Abstract]
  49. Kaneto H, Sharma A, Suzuma K, Laybutt DR, Xu G, Bonner-Weir S, Weir GC 2002 Induction of c-Myc expression suppresses insulin gene transcription by inhibiting NeuroD/BETA2-mediated transcriptional activation. J Biol Chem 277:12998–13006[Abstract/Free Full Text]
  50. German MS, Moss LG, Rutter WJ 1990 Regulation of insulin gene expression by glucose and calcium in transfected primary islet cultures. J Biol Chem 265:22063–22066[Abstract/Free Full Text]
  51. Melloul D, Ben-Neriah Y, Cerasi E 1993 Glucose modulates the binding of an islet-specific factor to a conserved sequence within the rat I and the human insulin promoters. Proc Natl Acad Sci USA 90:3865–3869[Abstract/Free Full Text]
  52. Lawrence MC, Bhatt HS, Easom RA 2002 NFAT regulates insulin gene promoter activity in response to synergistic pathways induced by glucose and glucagon-like peptide-1. Diabetes 51:691–698[Abstract/Free Full Text]
  53. Ohneda K, Mirmira RG, Wang J, Johnson JD, German MS 2000 The homeodomain of PDX-1 mediates multiple protein-protein interactions in the formation of a transcriptional activation complex on the insulin promoter. Mol Cell Biol 20:900–911[Abstract/Free Full Text]
  54. Peers B, Sharma S, Johnson T, Kamps M, Montminy M 1995 The pancreatic islet factor STF-1 binds cooperatively with Pbx to a regulatory element in the somatostatin promoter: importance of the FPWMK motif and of the homeodomain. Mol Cell Biol 15:7091–7097[Abstract]
  55. Asfari M, Janjic D, Meda P, Li G, Halban PA, Wollheim CB 1992 Establishment of 2-mercaptoethanol-dependent differentiated insulin-secreting cell lines. Endocrinology 130:167–178[Abstract]
  56. Kelpe CL, Moore PC, Parazzoli SD, Wicksteed B, Rhodes CJ, Poitout V 2003 Palmitate inhibition of insulin gene expression is mediated at the transcriptional level via ceramide synthesis. J Biol Chem 278:30015–30021[Abstract/Free Full Text]
  57. Wicksteed B, Herbert TP, Alarcon C, Lingohr MK, Moss LG, Rhodes CJ 2001 Cooperativity between the preproinsulin mRNA untranslated regions is necessary for glucose-stimulated translation. J Biol Chem 276:22553–22558[Abstract/Free Full Text]
  58. Briaud I, Harmon JS, Kelpe CL, Segu VB, Poitout V 2001 Lipotoxicity of the pancreatic ß-cell is associated with glucose-dependent esterification of fatty acids into neutral lipids. Diabetes 50:315–321[Abstract/Free Full Text]
  59. Schreiber E, Matthias P, Muller MM, Schaffner W 1989 Rapid detection of octamer binding proteins with ‘mini extracts,’ prepared from a small number of cells. Nucleic Acids Res 17:6419[Medline]
  60. Shih HM, Towle HC 1992 Definition of the carbohydrate response element of the rat S14 gene. Evidence for a common factor required for carbohydrate regulation of hepatic genes. J Biol Chem 267:13222–13228[Abstract/Free Full Text]
  61. Ericson J, Rashbass P, Schedl A, Brenner-Morton S, Kawakami A, van Heyningen V, Jessell TM, Briscoe J 1997 Pax6 controls progenitor cell identity and neuronal fate in response to graded Shh signaling. Cell 90:169–180[CrossRef][Medline]
  62. Ericson J, Thor S, Edlund T, Jessell TM, Yamada T 1992 Early stages of motor neuron differentiation revealed by expression of homeobox gene Islet-1. Science 256:1555–1560[Medline]